Texas Retina Associates | Arlington, TX

Research site

(Unclaimed)

Location

801 W. Randol Mill Road, Suite 101, Arlington, Texas, United States of America

Site insights

Top conditions

Top treatments

Ranibizumab

bevacizumab

LX211

Lampalizumab

Vamikibart

RO7200220

Abicipar Pegol

Triamcinolone Acetonide

ranibizumab

rapamycin

Parent organization

This site is a part of Texas Retina Associates

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 42 total trials

A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) (SIGLEC)

Investigate the Safety, Pharmacokinetics, and Treatment effects of Single and Multi-dose of Intravitreal AVD-104 in participants with geographic atro...

Active, not recruiting

Macular Degeneration

Geographic Atrophy of the Macula

Drug: AVD-104

Drug: Avacincaptad

A Study to Investigate Vamikibart (RO7200220) in Combination With Ranibizumab in Diabetic Macular Edema

Study BP43464 is a phase II, multicenter, randomized, double-masked active comparator-controlled study designed to assess the efficacy, safety, toler...

Active, not recruiting

Diabetic Macular Edema

Drug: Vamikibart

Drug: Ranibizumab

A Study to Investigate Vamikibart (RO7200220) in Diabetic Macular Edema

Study BP43445 is a phase II, multicenter, randomized, double-masked, active comparator-controlled study to investigate the efficacy, safety, tolerabi...

Active, not recruiting

Diabetic Macular Edema

Drug: Ranibizumab

Other: Sham Procedure

An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis (ELEVATE UC OLE)

The purpose of this open-label extension (OLE) study is to evaluate the safety and efficacy of etrasimod in participants with moderately to severely...

Active, not recruiting

Ulcerative Colitis

Drug: Etrasimod

Extension Study for the Port Delivery System With Ranibizumab (Portal)

This study will evaluate the long-term safety and tolerability of the Port Delivery System with ranibizumab (PDS) (100 mg/mL) in patients with neovas...

Enrolling

Neovascular Age-Related Macular Degeneration

Drug: PDS Implant with Ranibizumab 100 mg/mL

Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD (ASCENT)

RGX-314 is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AM...

Enrolling

Wet Age-related Macular Degeneration

WetAMD

Genetic: RGX-314 Dose 2

Biological: Aflibercept (EYLEA®)

This Study Will Evaluate the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Participants With Diabetic Macular Edema Compared With Intravitreal Ranibizumab (Pagoda)

This study will evaluate the efficacy, safety, and pharmacokinetics of the Port Delivery System with Ranibizumab (PDS) in Participants with Diabetic...

Active, not recruiting

Diabetic Macular Edema

Drug: PDS Implant Pre-Filled with 100 mg/mL Ranibizumab

Drug: Intravitreal Ranibizumab 0.5 mg Injection